Community-based Neuroendocrine Tumor (NET) Research Study

Inclusion Criteria:

- Histologically confirmed locally advanced or metastatic, well-differentiated
neuroendocrine tumor (NET) of the small bowel, stomach, colon/rectum, or pancreas (low
or intermediate grade; i.e. G1 or G2)

- Treatment with lanreotide depot (Somatostatin Analogue-naïve patients and patients
with prior treatment with octreotide long-acting repeatable (LAR) are permitted)

- Radiographically measurable disease

- Has signed the most recent written Patient Informed Consent Form

Exclusion Criteria:

- Known hypersensitivity to lanreotide

- Poorly differentiated or high grade carcinoma, or patients with neuroendocrine tumors
not of lung or thymic origin

- Patients who have previously initiated treatment with lanreotide depot prior to the
start of the study cannot have progressed between lanreotide initiation and study
entry

- Significant history of uncontrolled cardiac disease (ie, myocardial infarction within
6 months prior to enrollment or has congestive heart failure, uncontrolled angina,
severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities)